HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. - Wikidata - thesis-toulmin - TriplyDB

HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.

HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.

http://www.wikidata.org/entity/Q33842416

about

Role of histone deacetylases in pancreas: Implications for pathogenesis and therapy Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.Selective TRAIL-triggered apoptosis due to overexpression of TRAIL death receptor 5 (DR5) in P-glycoprotein-bearing multidrug resistant CEM/VBL1000 human leukemia cells Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5 Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery.Gene-by-Environment Interactions in Pancreatic Cancer: Implications for Prevention.Pancreatic ductal adenocarcinoma: a review of immunologic aspects.Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.Discovery of a Novel HDAC2 Inhibitor by a Scaffold-Merging Hybrid Query Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer.Down-Regulation of Ca2+-Activated K⁺ Channel KCa1.1 in Human Breast Cancer MDA-MB-453 Cells Treated with Vitamin D Receptor Agonists.Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts.Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma.Possible role of autophagy in the treatment of pancreatic cancer with histone deacetylase inhibitors.Overexpression of histone deacetylase 2 predicts unfavorable prognosis in human gallbladder carcinoma.HDAC2 promotes loss of primary cilia in pancreatic ductal adenocarcinoma.Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.HDACs and HDAC Inhibitors in Cancer Development and Therapy.c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells.Synergistic anticancer activity of valproate combined with nicotinamide enhances anti-proliferation response and apoptosis in MIAPaca2 cells.HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation.The 'N-factors' in pancreatic cancer: functional relevance of NF-κB, NFAT and Nrf2 in pancreatic cancer.Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.Sodium valproate inhibits the growth of human cholangiocarcinoma in vitro and in vivo.Low-dose valproic acid with low-dose gemcitabine augments MHC class I-related chain A/B expression without inducing the release of soluble MHC class I-related chain A/B.Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.Natural Agents-Mediated Targeting of Histone Deacetylases.Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects.Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.HDAC4 degradation by combined TRAIL and valproic acid treatment induces apoptotic cell death of TRAIL-resistant head and neck cancer cells HADC regulates the diabetic vascular endothelial dysfunction by targetting MnSOD

P2860

Q26774080-8D1E1F79-9EF0-4794-809C-75869AF02389 Q33936620-6697764F-3529-47AF-A93A-9DE4B96A2136 Q34193833-8839FAA9-B24F-4201-9BEF-2BBFC4761D54 Q34292461-3D883E6E-3DDB-48A8-96F0-3928D08C318F Q34608366-247FA209-B56E-44F0-8F13-22A57A823973 Q34670118-28A57764-37F2-45D9-8D9F-932B0A6B3822 Q35870682-CE22F9DB-11C5-4036-848A-C88685E77D7D Q35975127-A66240D9-1133-4D01-8F29-A4776F00109C Q36368454-455E681F-3B22-45A2-8ADE-5FE30F3E5943 Q37416288-AA93C438-677B-469E-8F91-1BC514AF982C Q37534790-30195466-144A-4416-80E1-97997059813A Q37745937-9517F4C9-AD4E-41A7-BE4A-9A021FE4BEDB Q37832684-7278B4CA-7B26-4600-807B-8461628CE035 Q38166587-A7ADDD21-2785-4E92-AC19-456408591C16 Q38398975-CD47AAD0-73BC-4991-9502-F01893B136E6 Q38724070-07664315-7695-45B8-A88E-3B0D2BBA9547 Q38829403-8CAFAA70-01F3-45B6-805F-BC17073D4B25 Q38947405-E675921D-8027-4658-877B-EDAFECD1F3BB Q38949421-590BA0CF-2937-43FB-9734-8E1B1EC44C57 Q39018558-FC8B17C2-9DA6-420F-9B5D-B22460B44D5B Q39307665-DE8D1493-95AE-42FB-A8D1-A2A7816DC044 Q39400148-13C8A405-79EF-494C-A805-8062332110FB Q39670791-2AEFEBF1-113E-4F7E-B5A3-A32CBC6A9C85 Q40951274-6FE3E30A-6D68-4C70-B617-D983FB8601C6 Q42734243-873A63DE-3E0C-4101-B4F2-A48965302D45 Q45759422-C3F2784D-79C7-4E0C-A75D-C01586E0AAD8 Q47645910-43757678-CC74-43DD-80E3-F87B871C7ACF Q47740361-31FDB688-384A-4BC4-9423-4E3B38332FA1 Q51034578-5DEC5B17-DDD7-447D-902C-C4034D01A8F3 Q52795326-F06A488A-B936-4106-8123-1383509EAB4B Q58730696-B1EEDEE4-38A3-4BD6-B435-C34BEA0FEA04 Q59126000-CA7CCBAA-F403-422B-B638-995FFD805440

P2860

HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.

http://www.wikidata.org/entity/Q33842416

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.

@ast

HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.

@en

type

label

HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.

@ast

HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.

@en

prefLabel

HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.

@ast

HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.

@en

P1433

Q33842416-C2EF6830-C268-4EBF-AC0F-D72A51C96562

P1476

Q33842416-AB60ED70-E663-455B-8E9D-F30F9564AAEF

P2093

Q33842416-3E199879-3693-47D7-A2F5-0BB0BACF1A61

Q33842416-7506076E-4C5B-4E3A-A749-FD428FE2B4BB

Q33842416-86C127C3-869D-4036-B97A-9A1B38C2C6D3

Q33842416-B6F8F480-94F9-4C50-A6F1-1BC276E3A58F

Q33842416-CF76ADEF-5D7D-4DFC-81B7-B44C0B8AF64E

Q33842416-F7595A33-22AE-4CBB-AA7E-6E6E6E67388A

P2860

Q33842416-01BD6636-9478-4A13-85DC-8227317BF3EF

Q33842416-01FB6CDD-6941-4E18-9BB3-B96CCF71C593

Q33842416-03870F4E-137F-42E4-8A83-A19A2689408B

Q33842416-038A3DFB-4EF7-498D-9DCA-7D5AED3EDFED

Q33842416-0518BCA3-6AE7-4DD7-B6AD-8690D3B63DDD

Q33842416-0577AE2E-9D20-4172-A82E-7DAAC9D6FAF3

Q33842416-08C43E61-9E09-42E9-8C1E-6C0C29F876EE

Q33842416-112C1897-5E08-401C-9E80-DE6815161CDB

Q33842416-1A8FBB11-11A9-42FB-923B-744BD18C3215

Q33842416-20ACC29D-2646-4EE7-9C90-2B027C681D00

P2888

Q33842416-D40F7FF3-C5E5-497D-A785-D77D2E61CE85

P304

Q33842416-0251E131-8A7E-4D39-837C-046E5468B97F

P31

Q33842416-260D5143-89FD-439E-BCC5-027FCA3C9AEF

P356

Q33842416-26B145C6-8ABA-4C0D-9186-634FEBB83B12

P478

Q33842416-2776A96B-A98E-4C96-B6B8-C3605C72329D

P50

Q33842416-ADC85B79-9B97-48E8-A195-F57AAFF29974

P577

Q33842416-E64E16CE-E847-4983-809B-5D83C7574842

P5875

Q33842416-8813497F-1D97-41D7-BC10-3A18096F483D

P6179

Q33842416-E9A8FCB7-019C-4C40-9658-00E3690D731C

P698

Q33842416-7C54395C-819D-4FE2-973D-84254FB379E9

P932

Q33842416-62E02095-A4A8-4055-829E-74E5D2BBC999

P356

P1433

Molecular Cancer

P1476

HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells

@en

P2093

Dieter Saur

http://www.w3.org/2001/XMLSchema#string

Günter Schneider

http://www.w3.org/2001/XMLSchema#string

Petra Fritsche

http://www.w3.org/2001/XMLSchema#string

Roland M Schmid

http://www.w3.org/2001/XMLSchema#string

Sandra Diersch

http://www.w3.org/2001/XMLSchema#string

Susanne Schüler

http://www.w3.org/2001/XMLSchema#string

P2860

CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells

HDAC2 regulates chromatin plasticity and enhances DNA vulnerability

Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling

Histone deacetylase inhibitors: Potential in cancer therapy

Death and anti-death: tumour resistance to apoptosis

Histone deacetylases and cancer

Acetylation of non-histone proteins modulates cellular signalling at multiple levels

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

P2888

P304

80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1476-4598-9-80

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43181002

http://www.w3.org/2001/XMLSchema#string

P6179

1048353734

http://www.w3.org/2001/XMLSchema#string

P698

20398369

http://www.w3.org/2001/XMLSchema#string

P932

2867820

http://www.w3.org/2001/XMLSchema#string